RDI vs NUVL vs CNK vs KROS

For growth investors, Keros Therapeutics, Inc.

(KROS) is the stronger pick with 67. 7% revenue growth year-over-year, versus -5. 5% for Reading International, Inc. (RDI). Keros Therapeutics, Inc. (KROS) offers the better valuation at 5. 1x trailing P/E, making it the more compelling value choice. Analysts rate Nuvalent, Inc. (NUVL) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Keros Therapeutics, Inc.

(KROS) is the cheapest at 5. 1x versus Cinemark Holdings, Inc. at 26. 4x.

Over the past 5 years, Nuvalent, Inc.

(NUVL) delivered a total return of +446. 1%, compared to -82. 1% for Reading International, Inc. (RDI). Over 10 years, the gap is even starker: NUVL returned +446. 1% versus RDI's -92. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cinemark Holdings, Inc.

(CNK) is the lower-risk stock at 0. 22β versus Nuvalent, Inc. 's 1. 09β — meaning NUVL is approximately 401% more volatile than CNK relative to the S&P 500. On balance sheet safety, Keros Therapeutics, Inc. (KROS) carries a lower debt/equity ratio of 6% versus 9% for Cinemark Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Keros Therapeutics, Inc.

(KROS) is pulling ahead at 67. 7% versus -5. 5% for Reading International, Inc. (RDI). On earnings-per-share growth, the picture is similar: Keros Therapeutics, Inc. grew EPS 146. 0% year-over-year, compared to -49. 5% for Cinemark Holdings, Inc.. Over a 3-year CAGR, RDI leads at 14. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Keros Therapeutics, Inc.

(KROS) is the more profitable company, earning 35. 7% net margin versus -16. 8% for Reading International, Inc. — meaning it keeps 35. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KROS leads at 28. 9% versus -6. 7% for RDI. At the gross margin level — before operating expenses — KROS leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for KROS: 781.

4% to $102. 60.

In this comparison, CNK (1.

1% yield) pays a dividend. RDI, NUVL, KROS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Cinemark Holdings, Inc.

(CNK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 22), 1. 1% yield). Both have compounded well over 10 years (CNK: -6. 6%, KROS: -42. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RDI (Communication Services) and NUVL (Healthcare) and CNK (Communication Services) and KROS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RDI is a small-cap quality compounder stock; NUVL is a small-cap quality compounder stock; CNK is a small-cap quality compounder stock; KROS is a small-cap high-growth stock. CNK pays a dividend while RDI, NUVL, KROS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.